Anokion is a clinical-stage biotech company that aims to improve autoimmune disease treatment, which typically involves systemic immunosuppression, leaving patients vulnerable to viruses, bacteria, and pathogens. Their science focuses on immune tolerance, the body’s ability to recognize its own antigens and not attack its own cells. They hope to address the underlying causes of autoimmune disease and restore immune tolerance by targeting pathways in the liver, using their immune tolerance platform. Some of the autoimmune diseases Anokion is developing therapies for include Celiac Disease, Multiple Sclerosis, and type I Diabetes. Anokion was founded in Switzerland in 2015.

Anokion

Drug notes:

About:

Jobs: